LAS VEGAS, Feb. 2, 2005 (PRIMEZONE) -- Herbal Regenesis, Inc., a seventh-generation family-owned herbal supplement company specializing in custom formulations to promote good health, has merged into Fedelitas Management, Inc., (Pink Sheets:FDLM) a Nevada Corporation, and will emerge as HerbalOne, Inc., the company's Chief Executive Officer, Dr. Chenle, Ph.D, announced today.
HerbalOne, formed more than 25 years ago, will shortly launch a national campaign to increase its visibility and to make its unique, protected products available to the general population. Heretofore, HerbalOne's specialized formulations were offered only to a select group of well-known entertainment and business community leaders.
"The opportunity to expand our ancient secrets of better health to the public, who today are more informed and conscious of the many hazards presented by our stressful lives, cannot be missed by our Company," Dr. Chenle said. "We are dedicated to sharing our formerly private knowledge, compiled over many centuries, with the widest possible audience. It is why we are in business, and is a mandate passed down to us from many generations of ancestors."
HerbalOne has retained the services of Innovation Advertising & Marketing, Inc., a leading Direct Response company, whose President and Chief Executive Officer, Robert Blagman, noted, "Dr. Chenle's reputation in the Chinese herbal medicine universe is impeccable. We have personally investigated many cases where HerbalOne's principals and procedures were instrumental in relieving stress-related difficulties. We are pleased and honored to be able to bring this unique line of products to the public consciousness."
Except for historical information contained herein, the matters set forth in this press release, such as statements relating to the Company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including timely development and acceptance of new products, the impact of competitive products and pricing, the timely development and release of products by suppliers, and other risks detailed in the Company's Registration Statement filed with the SEC.